A recent high-throughput screen has identified another TXNIP inhibitor SRI-37330, which significantly decreased TXNIP expression, glucagon secretion, and hepatic glucose output, thereby being championed as a potential treatment for diabetes [172]. This evidence concerns the gene TXNIP and diabetes mellitus.